Following the patent expiration of DPP-4 inhibitor Trajenta (linagliptin), combinatory drugs containing linagliptin have been released. Next month, a combinatory drug containing linagliptin combined with SGLT-2 inhibitory dapagliflozin will enter the market. It is a combinatory drug with a new combination being introduced in South Korea.

According to the industry sources on June 24th, Aju Pharm’s 'Dapalina Tab,' containing dapagliflozin propanediol hydrate combined with linagliptin, will be listed for reimbursement on July 1st.

It is a combinatory drug with a new combination of SGLT-2 inhibitory dapagliflozin with DPP-4 inhibitor linagliptin. The Ministry of Food and Drug Safety (MFDS) cat